1.4 Billion Reasons Valeant Thinks It's Got Allergan

Valeant Pharmaceuticals'  management wasn't satisfied with just discussing one deal today (their proposed takeover of Allergan  -- they also revealed a $1.4 billion sale to Nestle  this morning.

Valeant is selling several skin care drugs to Nestle, some of which are Botox competitors, in a sign of its confidence in the Allergan transaction. After all, if the Allergan buyout goes through, there could be potential antitrust issues with Botox if these assets aren't sold off.

Valeant's getting out ahead of that potential issue by selling the portfolio to Nestle -- and at five times sales, it's a pretty good price.

Watch the video below, in which Motley Fool health care analysts Michael Douglass and David Williamson discuss the deal, the implications for Valeant/Allergan, and why Nestle is interested in skin care.

Valeant has been on a tear these past five years -- but can it keep up with this top stock for 2014?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

The article 1.4 Billion Reasons Valeant Thinks It's Got Allergan originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story